Netris Pharma SAS has entered into a scientific collaboration agreement with Orano SA and the Centre Léon Bérard (CLB) to develop novel antibody-radio conjugates for the treatment of cancer.
Therapeutic Solutions International Inc. has announced promising data on the use of Campbellcell for treatment of bipolar disorder by the company's suicide prevention-based spin-off Campbell Neurosciences Inc.
SBT-101 (Swanbio Therapeutics Inc.) is an adeno-associated virus serotype 9 (AAV9)-based gene therapy that delivers a functional copy of the ABCD1 gene and is under development for the treatment of adrenomyeloneuropathy (AMN).
As therapeutics development in Alzheimer’s disease (AD) is broadening its search for therapeutic targets, one of the alternatives to amyloid-β, or at least to its direct targeting by monoclonal antibodies, that is coming into focus is triggering receptor expressed on myeloid cells 2 (TREM2). From a drug development standpoint, amyloid-β remains a mystery. Scientific evidence clearly suggests that amyloid misprocessing is an underlying factor in the development of AD, and it is certainly a reasonable hypothesis that reducing amyloid plaque should fight the disease.
Scientists from the University of Lisbon have described how telomeres can establish the maximum damage that a cancer cell can suffer. Above this threshold, the cell would stop dividing and die. The damage comes from the transcription of the telomeres themselves of an RNA molecule called TERRA. When TERRA’s levels increase, the cell can no longer multiply. This mechanism occurs in ALT (alternative lengthening of telomeres) cells, which do not elongate their telomeres through telomerase.
Jiangxi Jemincare Group Co. Ltd. and Shanghai Jemincare Pharmaceuticals Co. Ltd. have divulged tricyclic hypoxia inducible factor 2-alpha (HIF-2-alpha; EPAS1) inhibitors reported to be useful for the treatment of cancer, von Hippel-Lindau disease, pulmonary hypertension and inflammatory bowel disease.
Insilico Medicine IP Ltd. has described new TRAF2 and NCK-interacting protein kinase (TNIK) and/or mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4; HGK; MEKKK4) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Medshine Discovery Inc. has patented substituted pyridine-2,4-dione derivatives acting as cardiac myosin inhibitors. As such, they are reported to be useful for the treatment of hypertrophic cardiomyopathy and heart failure.
RSS
